匹多莫德联合布地奈德对3岁以上小儿支气管哮喘的治疗效果、肺功能指标及免疫功能指标的影响

Effect of pidotimod combined with budesonide on clinical efficacy,lung function and immune function in children older than 3 years with bronchial asthma

目的研究3岁以上小儿支气管哮喘患者进行匹多莫德联合布地奈德治疗后的治疗效果、肺功能指标及免疫功能指标的影响。方法选择112例3岁以上小儿支气管哮喘患者,分为观察组和对照组,对照组给予布地奈德治疗,观察组给予匹多莫德联合布地奈德治疗。比较分析两组患者治疗后的治疗效果、肺功能指标及免疫功能指标。结果观察组治疗后小儿支气管哮喘患者总有效率较对照组明显提高(χ2=6.40,P<0.05),且发作次数及发作持续时间均较对照组明显降低(t分别=3.54、7.36,P均<0.05)。观察组治疗后用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、呼气峰流速(PEF)以及Ig A、Ig G、Ig M水平、CD3+、CD4+/CD8+和自然杀伤细胞(NK)水平均较对照组明显提高(t分别=3.24、3.77、9.66、3.65、4.21、5.58、4.76、3.67、4.21,P均<0.05)。结论匹多莫德联合布地奈德可明显提高3岁以上小儿支气管哮喘患者的治疗效果,减少发作次数及发作持续时间,提高肺活量及免疫力。

Objective To observe the effect of pidotimod combined with budesonide on clinical efficacy,lung function and immune function in children older than 3 years with bronchial asthma.Methods A total of 112 cases of children older than 3 years with bronchial asthma were divided into two groups.Patients in the control group were given budesonide,while the patients in observation group were given pidotimod combined with budesonide.The clinical efficacy,lung function parameters and immune function parameters were compared.Results The total effective rate in observation group after treatment was significantly higher than the control group(χ2=6.40,P<0.05).Asthma attacks and duration of the observation group after treatment were significantly lower than those of the control group(t=3.54,7.36,P<0.05).The levels of the FVC,FEV1,PEF,IgA,IgG,IgM,CD3+,CD4+/CD8+and NK cells of the observation group after treatment were significantly higher than those of the control group(t=3.24,3.77,9.66,3.65,4.21,5.58,4.76,3.67,4.21,P<0.05).Conclusion Pidotimod combined with budesonide in the treatment of bronchial asthma can effectively enhance clinical efficacy,reduce asthma attacks and duration,and improve lung function and immune function.